Taro Pharmaceutical Industries Ltd is a prominent pharmaceutical company that has gained recognition for its innovative products, commitment to quality, and strong market presence. With a rich history spanning several decades, Taro has emerged as a trusted name in the global pharmaceutical industry.
This article aims to provide an overview of Taro Pharmaceutical Industries Ltd, highlighting its background, key milestones, product portfolio, global presence, and commitment to excellence.
Background and History
Taro Pharmaceutical Industries Ltd was founded in 1950 and is headquartered in Haifa, Israel. The company began as a small manufacturer of topical creams and ointments and steadily expanded its product offerings over the years. Taro’s early success can be attributed to its focus on research and development, which led to the creation of innovative pharmaceutical formulations.
Key Milestones
Taro Pharmaceutical Industries Ltd has achieved several significant milestones throughout its history. In 1983, the company went public and listed its shares on the New York Stock Exchange (NYSE). This move allowed Taro to increase its global visibility and attract investors. Subsequently, the company expanded its operations internationally, establishing subsidiaries in various countries, including Canada, the United Kingdom, and the Netherlands.
Financial statistic of Taro Pharmaceutical is as follows
Valuation Measures
| Market Cap (intraday) | 1.09B |
| Enterprise Value | 270.29M |
| Trailing P/E | 42.60 |
| Forward P/E | 9.81 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.90 |
| Price/Book (mrq) | 0.63 |
| Enterprise Value/Revenue | 0.47 |
| Enterprise Value/EBITDA | 5.42 |
Trading Information
Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change 3 | -19.74% |
| S&P500 52-Week Change 3 | 1.77% |
| 52 Week High 3 | 40.16 |
| 52 Week Low 3 | 22.89 |
| 50-Day Moving Average 3 | 26.33 |
| 200-Day Moving Average 3 | 29.47 |
Share Statistics
| Avg Vol (3 month) 3 | 21.01k |
| Avg Vol (10 day) 3 | 28.03k |
| Shares Outstanding 5 | 37.58M |
| Implied Shares Outstanding 6 | N/A |
| Float 8 | 8.09M |
| % Held by Insiders 1 | 78.48% |
| % Held by Institutions 1 | 12.58% |
| Shares Short (May 14, 2023) 4 | 69.16k |
| Short Ratio (May 14, 2023) 4 | 3.35 |
| Short % of Float (May 14, 2023) 4 | 0.86% |
| Short % of Shares Outstanding (May 14, 2023) 4 | 0.18% |
| Shares Short (prior month Apr 13, 2023) 4 | 49.3k |
Dividends & Splits
| Forward Annual Dividend Rate 4 | N/A |
| Forward Annual Dividend Yield 4 | N/A |
| Trailing Annual Dividend Rate 3 | 0.00 |
| Trailing Annual Dividend Yield 3 | 0.00% |
| 5 Year Average Dividend Yield 4 | N/A |
| Payout Ratio 4 | 0.00% |
| Dividend Date 3 | Dec 27, 2018 |
| Ex-Dividend Date 4 | Dec 09, 2018 |
| Last Split Factor 2 | 2:1 |
| Last Split Date 3 | Jul 26, 2001 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | Mar 30, 2023 |
| Most Recent Quarter (mrq) | Mar 30, 2023 |
Profitability
| Profit Margin | 4.44% |
| Operating Margin (ttm) | 3.09% |
Management Effectiveness
| Return on Assets (ttm) | 0.51% |
| Return on Equity (ttm) | 1.48% |
Income Statement
| Revenue (ttm) | 572.95M |
| Revenue Per Share (ttm) | 15.24 |
| Quarterly Revenue Growth (yoy) | 2.30% |
| Gross Profit (ttm) | N/A |
| EBITDA | 49.84M |
| Net Income Avi to Common (ttm) | 25.45M |
| Diluted EPS (ttm) | 1.74 |
| Quarterly Earnings Growth (yoy) | -74.80% |
Balance Sheet
| Total Cash (mrq) | 850.29M |
| Total Cash Per Share (mrq) | 22.62 |
| Total Debt (mrq) | N/A |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 3.47 |
| Book Value Per Share (mrq) | 46.05 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 31.75M |
| Levered Free Cash Flow (ttm) | 11.99M |
Credit – Yahoo Finance
In 2010, Taro became a fully-owned subsidiary of Sun Pharmaceutical Industries Ltd, one of the largest pharmaceutical companies in India. This strategic acquisition strengthened Taro’s position in the global market, providing access to a broader network of resources, expertise, and manufacturing capabilities.
Product Portfolio
Taro Pharmaceutical Industries Ltd offers a diverse range of products across multiple therapeutic categories. The company focuses on developing generic and branded prescription medications, over-the-counter drugs, and dermatological products. Taro’s product portfolio encompasses various therapeutic areas, including cardiovascular, dermatology, central nervous system, and anti-infective medications, among others.
The company’s commitment to research and development enables it to introduce new formulations and dosage forms, improving treatment options and patient care. Taro Pharmaceutical Industries Ltd adheres to stringent quality standards and regulatory requirements, ensuring the safety and efficacy of its products.
Global Presence
Taro Pharmaceutical Industries Ltd has established a strong global presence, with its products being marketed in over 25 countries worldwide. The company has subsidiaries and offices in North America, Europe, Asia, and other regions, allowing it to cater to the diverse healthcare needs of patients across different markets.
Taro’s international expansion has enabled it to collaborate with healthcare professionals, regulatory authorities, and distribution partners globally. By leveraging its extensive network, the company strives to make its products accessible to patients worldwide, contributing to the improvement of healthcare systems globally.
Commitment to Excellence
Taro Pharmaceutical Industries Ltd is renowned for its unwavering commitment to excellence in all aspects of its operations. The company emphasizes quality control, investing in state-of-the-art manufacturing facilities and adhering to rigorous quality assurance processes. Taro’s commitment to quality extends to its research and development initiatives, where it focuses on developing innovative pharmaceutical solutions to address unmet medical needs.
Furthermore, Taro places a strong emphasis on corporate responsibility and sustainability. The company actively engages in initiatives aimed at environmental conservation, community development, and promoting access to healthcare in underserved regions. Taro Pharmaceutical Industries Ltd’s dedication to social responsibility demonstrates its commitment to making a positive impact beyond the pharmaceutical industry.
Overall, Taro Pharmaceutical Industries Ltd has emerged as a leading player in the global pharmaceutical market, thanks to its rich history, dedication to quality, and diverse product portfolio. With a global presence and a commitment to excellence, Taro continues to make significant contributions to healthcare by providing innovative and affordable pharmaceutical solutions. As the company forges ahead, it remains focused on research and development, expanding its product offerings, and addressing evolving healthcare challenges to improve
